Crescendo Biologics and Takeda Enter Collaboration for Humabody®-based Therapeutics Worth up to $790m
Collaboration to generate tumor targeting drug conjugates and immuno-oncology therapeutics Crescendo Biologics Limited (Crescendo), the…
read more
Dr. Andrew Muir joined Midven in 2004. He is a Director of the Company and Fund Principal of the Rainbow Seed Fund and the Early Advantage fund.
After an initial scientific career at Zeneca he went on to roles in research and business development at the medical device company Biocompatibles and then Vice President of Technology for a US start-up in disinfection of medical equipment.
He started his career in VC with the £4m per annum Invention and Innovation seed capital fund at NESTA (the National Endowment for Science Technology and the Arts). He has a degree and a PhD in Chemistry from the University of Oxford.
Andrew combines a strong scientific and technical grounding with a real commercial pragmatism developed from his operational roles.
